logo
Chinese officials call on carmakers to clamp down on price spiral

Chinese officials call on carmakers to clamp down on price spiral

In discussions with major carmakers, China has repeatedly brought up the 'irrational competition' driving down prices – an economy-wide issue threatening the buoyancy of
emerging growth drivers , particularly new energy vehicles (NEVs) – calling for firms to establish lasting standards to ensure fair and orderly market activity.
As Beijing seeks to rein in a
cutthroat price war driving down growth potential in the sector – a trend that is also fuelling deflationary pressure – industry leaders gathered in the capital for two symposia held over two consecutive days, according to two statements released by the Ministry of Industry and Information Technology (MIIT) late Friday. Officials present instructed companies to take action and reverse the slide.
'It is vital to recognise the extreme urgency of curbing irrational competition in the NEV industry,' said Che Jun, deputy head of a central guiding group, at a meeting with the China Association of Automobile Manufacturers, the foremost trade association for carmakers. Representatives from Beijing Automotive Industry Holding and BYD also attended.
Guiding groups are dispatched by the Central Committee of the ruling Communist Party to provide supervision and guidance to localities and industries relevant to the group's designated area of focus.
Che stressed that the problem is prone to recurrence and therefore requires sustained, long-term efforts. Leading companies should set an example for the rest of the industry, he added, by engaging in lawful and rational market competition.
The other symposium was held by MIIT, the National Development and Reform Commission and the State Administration for Market Regulation, with representatives from 17 leading carmakers present. The assembled government bodies said healthy industrial development should be promoted through cost oversight and price monitoring.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

South China Morning Post

timean hour ago

  • South China Morning Post

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.

InvestHK at 25: powering growth for global firms in Hong Kong and beyond
InvestHK at 25: powering growth for global firms in Hong Kong and beyond

South China Morning Post

time2 hours ago

  • South China Morning Post

InvestHK at 25: powering growth for global firms in Hong Kong and beyond

When InvestHK was established in July 2000, its mission was clear: attract overseas and mainland Chinese companies to establish or expand in Hong Kong, reinforcing its position as 'Asia's world city'. Twenty-five years on, that mission remains unchanged, but the tools and the scale of support have evolved significantly. Advertisement This year, both InvestHK and Hong Kong Exchanges and Clearing (HKEX) marked their silver jubilees with notable results. In 2024, InvestHK assisted a record 539 mainland Chinese and overseas companies in setting up operations in Hong Kong. Since its establishment in 2000, 145 of InvestHK's clients have listed on HKEX. Between January 2023 and June 2025, InvestHK helped more than 1,300 companies set up or expand in Hong Kong, bringing in over HK$160 billion (US$20 billion) in foreign direct investment. These companies created more than 19,000 jobs in their first year of operation, exceeding the government's 2022 Policy Address targets ahead of schedule. Hong Kong's initial public offering (IPO) market has maintained steady momentum in 2025, with HKEX recording more than 50 listings between January and mid-July, a year-on-year increase of 30 per cent. The exchange ranked first globally in IPO fundraising during the period, with more than 200 companies actively preparing for a public offering in the second half of the year. Support from InvestHK for overseas and mainland Chinese companies and institutions includes planning, setting up and expanding their operations in Hong Kong. The agency provides strategic advice on market entry, practical guidance during the establishment and launch phases, and continued support as businesses grow and scale across international markets via Hong Kong. When an IPO is on the horizon, InvestHK offers pre-listing workshops covering disclosure, environmental, social and governance (ESG), and investor-relations requirements, enabling founders to scale up without needing to shift jurisdictions, a stability that is increasingly valued in an era of geopolitical uncertainty. Advertisement Beyond projects: building ecosystems

Hong Kong 47: third batch of opposition activists freed after 4 years in prison
Hong Kong 47: third batch of opposition activists freed after 4 years in prison

South China Morning Post

time2 hours ago

  • South China Morning Post

Hong Kong 47: third batch of opposition activists freed after 4 years in prison

Three more activists among the 47 Hong Kong opposition figures charged in the city's largest national security case for conspiracy to commit subversion have been released from prison. Former union leader Carol Ng Man-yee, and activists Nathan Lau Chak-fung and Frankie Fung Tak-chun were the third batch of defendants in the landmark case to complete their four-year-and-five-month sentences. The trio, who pleaded guilty, were separately sent to their residences in vans from the Lo Wu Correctional Institution and Stanley Prison on Monday morning. Asked about his feelings, Lau put on a smile and shook his head while walking towards his block. Nathan Lau was freed from prison after completing his sentence under the national security law. Photo: Handout Lau, 28, was the president of the student union at Hong Kong Shue Yan University and a standing committee member of the Hong Kong Federation of Students. Ng, now 54, was a flight attendant at British Airways. She founded the BA Hong Kong International Cabin Crew Association and had mounted several legal challenges against the employer over wages, anti-union practices, age and sex discrimination.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store